Skip to main content
XCUR
NASDAQ Life Sciences

Exicure Appoints New Director and Chief Operating Officer, Strengthening Governance and Operations

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$3.777
Mkt Cap
$24.074M
52W Low
$3.101
52W High
$12.652
52W Position info
22% above low
Off High info
70% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

XCUR sits 22% above its 52-week low of $3.101 on light trading volume (0.3× avg).

Summary

Exicure, Inc. announced the appointment of Yoontae Han as a new director and Young Seung Ko as Chief Operating Officer, alongside a new Audit Committee Chair, signaling efforts to bolster leadership and financial oversight.


Key Events · Executive and Board Changes · XCUR

  • New Director Appointed

    Yoontae Han was appointed to the Board of Directors, effective April 8, 2026, and will also serve on the Audit Committee. He will receive an annual retainer of $20,000.

  • Audit Committee Leadership Change

    Dongho Lee, a current member of the Audit Committee, has been appointed to serve as its Chair.

  • Chief Operating Officer Appointed

    Young Seung Ko was appointed as the Chief Operating Officer, effective April 9, 2026. Mr. Ko brings extensive experience in public company operations, financial reporting, internal controls, and corporate governance. The company will pay an additional monthly fee of $10,000 to Innocircle Advisors Inc. for these COO services.


Analysis · XCUR · Life Sciences

This filing indicates Exicure, Inc. is actively working to strengthen its leadership and governance, which is a positive signal given the company's previously disclosed 'going concern' warning. The appointment of Yoontae Han to the Board and Audit Committee, alongside Dongho Lee's promotion to Audit Committee Chair, enhances financial oversight. Crucially, the new Chief Operating Officer, Young Seung Ko, brings over 20 years of global experience in public company operations, financial reporting, internal controls, and corporate governance, directly addressing areas of concern for a company in distress. These changes suggest a concerted effort to stabilize operations and improve financial management.

At the time of this filing, XCUR was trading at $3.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.1M. The 52-week trading range was $3.10 to $12.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XCUR - Latest Insights

XCUR
Jul 17, 2026, 4:39 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $1.63
Real-time Price: $1.74 info
Change: +$0.110 (+7%) info
Market Cap: $11.091M info
XCUR
Jul 17, 2026, 1:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $1.67
Real-time Price: $1.74 info
Change: +$0.075 (+5%) info
Market Cap: $11.091M info
XCUR
Jun 30, 2026, 3:03 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.74 info
Change: -$0.2616 (-13%) info
Market Cap: $11.091M info
XCUR
Jun 30, 2026, 2:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.03
Real-time Price: $1.74 info
Change: -$0.290 (-14%) info
Market Cap: $11.091M info
XCUR
May 29, 2026, 2:09 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.16
Real-time Price: $1.74 info
Change: -$1.42 (-45%) info
Market Cap: $11.091M info